Published in Biochem J on March 15, 2003
Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell (2009) 8.69
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol (2008) 6.90
Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov (2012) 6.70
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A (2004) 3.86
Lessons from the genome sequence of Neurospora crassa: tracing the path from genomic blueprint to multicellular organism. Microbiol Mol Biol Rev (2004) 3.67
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A (2007) 3.60
Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol (2006) 3.37
SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev (2007) 3.34
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 3.20
Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol (2004) 3.00
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol (2010) 2.94
Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron (2008) 2.88
Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med (2005) 2.72
Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet (2008) 2.55
Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc (2010) 2.50
Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J (2008) 2.44
Histone modifications affect timing of oligodendrocyte progenitor differentiation in the developing rat brain. J Cell Biol (2005) 2.34
An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors. J Am Chem Soc (2010) 2.30
A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol (2009) 2.30
Phosphorylation regulates SIRT1 function. PLoS One (2008) 2.30
Proteomics of herpes simplex virus replication compartments: association of cellular DNA replication, repair, recombination, and chromatin remodeling proteins with ICP8. J Virol (2004) 2.27
Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol Cell Biol (2007) 2.25
SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol (2005) 2.24
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23
How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol (2006) 2.14
The microRNA miR-22 inhibits the histone deacetylase HDAC4 to promote TH17 cell-dependent emphysema. Nat Immunol (2015) 2.13
Fluorous-based small-molecule microarrays for the discovery of histone deacetylase inhibitors. Angew Chem Int Ed Engl (2007) 2.11
Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem (2008) 2.09
IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300. Mol Cell Biol (2006) 2.05
Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis (2005) 2.05
Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem (2008) 2.04
Activity-based probes for proteomic profiling of histone deacetylase complexes. Proc Natl Acad Sci U S A (2007) 2.03
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A (2007) 2.03
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res (2010) 2.01
Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood) (2007) 1.98
Involvement of the histone deacetylase SIRT1 in chicken ovalbumin upstream promoter transcription factor (COUP-TF)-interacting protein 2-mediated transcriptional repression. J Biol Chem (2003) 1.93
SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol (2004) 1.89
MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A (2006) 1.82
Re-employment of developmental transcription factors in adult heart disease. Semin Cell Dev Biol (2006) 1.82
Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure. J Mol Cell Cardiol (2007) 1.81
Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J (2003) 1.80
High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem (2010) 1.79
The role of HDAC6 in cancer. J Biomed Biotechnol (2010) 1.77
Acetylation of estrogen receptor alpha by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor. Mol Endocrinol (2006) 1.73
Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta (2011) 1.73
Histone-modifying complexes regulate gene expression pertinent to the differentiation of the protozoan parasite Toxoplasma gondii. Mol Cell Biol (2005) 1.72
The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci U S A (2006) 1.71
Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors. Biochemistry (2008) 1.68
HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol (2012) 1.67
HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat Neurosci (2009) 1.67
The impact of acetylation and deacetylation on the p53 pathway. Protein Cell (2011) 1.66
Regulation of cartilage-specific gene expression in human chondrocytes by SirT1 and nicotinamide phosphoribosyltransferase. J Biol Chem (2008) 1.66
Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke. Am J Respir Cell Mol Biol (2008) 1.64
Coding exons function as tissue-specific enhancers of nearby genes. Genome Res (2012) 1.64
Regulation of nuclear translocation of HDAC3 by IkappaBalpha is required for tumor necrosis factor inhibition of peroxisome proliferator-activated receptor gamma function. J Biol Chem (2005) 1.63
Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics (2012) 1.61
The placenta: transcriptional, epigenetic, and physiological integration during development. J Clin Invest (2010) 1.61
"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology (2009) 1.59
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene (2008) 1.59
Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res (2006) 1.58
Tumor necrosis factor alpha-mediated reduction of KLF2 is due to inhibition of MEF2 by NF-kappaB and histone deacetylases. Mol Cell Biol (2005) 1.57
HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Dev Neurobiol (2008) 1.56
Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol (2010) 1.55
Myt1 family recruits histone deacetylase to regulate neural transcription. J Neurochem (2005) 1.54
Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis (2011) 1.54
Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol (2009) 1.53
Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription. Mol Cell Proteomics (2012) 1.49
Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy. J Biol Chem (2008) 1.48
Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. Blood (2006) 1.48
The epigenetics of autoimmunity. Cell Mol Immunol (2011) 1.47
Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proc Natl Acad Sci U S A (2011) 1.46
Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis (2005) 1.46
Histone deacetylase inhibitors modify pancreatic cell fate determination and amplify endocrine progenitors. Mol Cell Biol (2008) 1.46
Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther (2010) 1.45
Nuclear receptor co-repressors are required for the histone-deacetylase activity of HDAC3 in vivo. Nat Struct Mol Biol (2013) 1.43
HDAC1/2-Dependent P0 Expression Maintains Paranodal and Nodal Integrity Independently of Myelin Stability through Interactions with Neurofascins. PLoS Biol (2015) 1.41
Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays. PLoS One (2015) 1.40
Regulation of HIF-1{alpha} activity in adipose tissue by obesity-associated factors: adipogenesis, insulin, and hypoxia. Am J Physiol Endocrinol Metab (2011) 1.39
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics (2013) 1.38
Lysine deacetylation in ischaemic preconditioning: the role of SIRT1. Cardiovasc Res (2010) 1.38
Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol (2008) 1.38
Hopx and Hdac2 interact to modulate Gata4 acetylation and embryonic cardiac myocyte proliferation. Dev Cell (2010) 1.38
Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther (2005) 1.37
The NF-kappaB p50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes. J Hepatol (2010) 1.37
Neuroprotection by histone deacetylase-related protein. Mol Cell Biol (2006) 1.37
Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood (2007) 1.36
HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res (2008) 1.36
Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease. Toxicol Appl Pharmacol (2011) 1.35
Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis (2007) 1.35
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension (2010) 1.35
PP2A regulates HDAC4 nuclear import. Mol Biol Cell (2007) 1.34
Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy. Cancer Gene Ther (2005) 1.34
Mapping the LINE1 ORF1 protein interactome reveals associated inhibitors of human retrotransposition. Nucleic Acids Res (2013) 1.31
The p68 and p72 DEAD box RNA helicases interact with HDAC1 and repress transcription in a promoter-specific manner. BMC Mol Biol (2004) 1.31
Epigenetic effects of ethanol on liver and gastrointestinal injury. World J Gastroenterol (2006) 1.29
Epigenetic aberrations and cancer. Mol Cancer (2006) 1.29
Epigenetic regulation of thy-1 by histone deacetylase inhibitor in rat lung fibroblasts. Am J Respir Cell Mol Biol (2010) 1.29
Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy. Brain Pathol (2010) 1.27
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs (2010) 1.27
The language of covalent histone modifications. Nature (2000) 44.92
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
HDAC6 is a microtubule-associated deacetylase. Nature (2002) 12.76
The human transcriptome map: clustering of highly expressed genes in chromosomal domains. Science (2001) 12.35
A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature (1997) 9.71
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem (1990) 9.21
Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer (2001) 9.12
Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature (1998) 8.75
Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature (2000) 8.59
The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol (2000) 8.47
Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev (1999) 7.58
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 7.47
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov (2002) 6.97
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J (2001) 6.85
DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet (2000) 6.57
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A (2000) 5.53
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst (2000) 5.21
Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell (2002) 5.19
The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol (2001) 4.92
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res (2002) 4.90
The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr (1996) 4.62
The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol (2001) 4.55
Microarray deacetylation maps determine genome-wide functions for yeast histone deacetylases. Cell (2002) 4.38
Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev (2000) 4.00
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A (1999) 3.26
Histone deacetylases, transcriptional control, and cancer. J Cell Physiol (2000) 3.18
Control of muscle development by dueling HATs and HDACs. Curr Opin Genet Dev (2001) 3.17
Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol (2000) 3.13
Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes. EMBO J (1999) 3.11
Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol Cell Biol (2002) 2.93
Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol (2001) 2.91
The human histone deacetylase family. Exp Cell Res (2001) 2.86
Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem (2002) 2.82
Functional significance of histone deacetylase diversity. Curr Opin Genet Dev (2001) 2.79
Regulation of transcription factor YY1 by acetylation and deacetylation. Mol Cell Biol (2001) 2.72
Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem (2000) 2.67
Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst (1998) 2.64
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res (2001) 2.50
Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res (2000) 2.47
Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7. J Biol Chem (2001) 2.41
Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem (1993) 2.40
Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene (1998) 2.27
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood (2001) 2.25
Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci U S A (2001) 2.23
Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem (2000) 2.19
Cloning and characterization of a histone deacetylase, HDAC9. Proc Natl Acad Sci U S A (2001) 2.19
Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol Chem (2001) 2.18
Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res (2001) 2.15
Histone acetylation and disease. Cell Mol Life Sci (2001) 2.11
Histone deacetylase 1 phosphorylation promotes enzymatic activity and complex formation. J Biol Chem (2001) 2.08
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res (2001) 2.08
Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst (2002) 2.06
Functional domains of histone deacetylase-3. J Biol Chem (2002) 2.05
Class II histone deacetylases: structure, function, and regulation. Biochem Cell Biol (2001) 2.00
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest (2001) 2.00
Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression. Genes Dev (2002) 1.99
Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem (2001) 1.97
Histone acetylation beyond promoters: long-range acetylation patterns in the chromatin world. Bioessays (2001) 1.88
Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet (2001) 1.87
Functional divergence between histone deacetylases in fission yeast by distinct cellular localization and in vivo specificity. Mol Cell Biol (2002) 1.84
Histone deacetylase as a therapeutic target. Trends Endocrinol Metab (2001) 1.83
Functional and physical interaction between the histone methyl transferase Suv39H1 and histone deacetylases. Nucleic Acids Res (2002) 1.77
Stra13 expression is associated with growth arrest and represses transcription through histone deacetylase (HDAC)-dependent and HDAC-independent mechanisms. Proc Natl Acad Sci U S A (2000) 1.73
Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5. Proc Natl Acad Sci U S A (2000) 1.71
A dynamic role for HDAC7 in MEF2-mediated muscle differentiation. J Biol Chem (2001) 1.68
Identification of a nuclear domain with deacetylase activity. Proc Natl Acad Sci U S A (2000) 1.64
A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res (2000) 1.53
Phosphatase inhibition leads to histone deacetylases 1 and 2 phosphorylation and disruption of corepressor interactions. J Biol Chem (2002) 1.52
Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res (1999) 1.51
Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res (2002) 1.50
Differential localization of HDAC4 orchestrates muscle differentiation. Nucleic Acids Res (2001) 1.49
Isolation and characterization of a novel class II histone deacetylase, HDAC10. J Biol Chem (2001) 1.48
Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene (2001) 1.47
DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res (2001) 1.45
Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Lett (2001) 1.44
Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J Biol Chem (2001) 1.43
Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem J (2000) 1.42
Homo-oligomerisation and nuclear localisation of mouse histone deacetylase 1. J Mol Biol (2001) 1.38
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res (2001) 1.34
Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic Acids Res (2002) 1.33
SMRTE inhibits MEF2C transcriptional activation by targeting HDAC4 and 5 to nuclear domains. J Biol Chem (2001) 1.32
Histone deacetylase 3 associates with and represses the transcription factor GATA-2. Blood (2001) 1.30
Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. Cancer Res (1999) 1.25
The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res (2001) 1.24
Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol (2001) 1.24
Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem (2002) 1.23
Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. J Mammary Gland Biol Neoplasia (2001) 1.23
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res (2002) 1.23
Cloning and characterization of human histone deacetylase 8. FEBS Lett (2000) 1.22
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene (1999) 1.22
Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol (2001) 1.21
The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp Cell Res (2002) 1.21
Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc Natl Acad Sci U S A (1998) 1.19
Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res (2000) 1.17
Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate. Biochem Biophys Res Commun (1998) 1.15
Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol (2001) 1.13
Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res (2001) 1.13
Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. Cancer Res (2001) 1.12
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One (2008) 5.86
Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA (2007) 5.74
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature (2012) 4.53
Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer (2006) 2.99
X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis (2012) 2.28
X-linked adrenoleukodystrophy in women: a cross-sectional cohort study. Brain (2014) 2.16
Induced hypothermia is protective in a rat model of pneumococcal pneumonia associated with increased adenosine triphosphate availability and turnover*. Crit Care Med (2012) 2.02
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet (2012) 1.96
Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med (2010) 1.87
High incidence of malformation syndromes in a series of 1,073 children with cancer. Am J Med Genet A (2005) 1.85
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci U S A (2009) 1.66
Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol (2011) 1.62
Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clin Chem (2009) 1.62
High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol (2012) 1.53
Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res (2008) 1.50
A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer (2012) 1.49
Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev (2011) 1.31
Analysis of very long-chain fatty acids using electrospray ionization mass spectrometry. Mol Genet Metab (2003) 1.28
Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev (2009) 1.28
Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum Mol Genet (2008) 1.27
The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy. EMBO Mol Med (2010) 1.26
Late-onset MNGIE due to partial loss of thymidine phosphorylase activity. Ann Neurol (2005) 1.25
Prognostic factors for progression of childhood optic pathway glioma: a systematic review. Eur J Cancer (2006) 1.22
Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosomes Cancer (2003) 1.21
Arts syndrome is caused by loss-of-function mutations in PRPS1. Am J Hum Genet (2007) 1.20
Quantitative and compositional study of cardiolipin in platelets by electrospray ionization mass spectrometry: application for the identification of Barth syndrome patients. Clin Chem (2002) 1.20
Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev (2010) 1.20
Prevalence and patterns of morphological abnormalities in patients with childhood cancer. JAMA (2008) 1.18
Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer (2008) 1.18
A novel defect of peroxisome division due to a homozygous non-sense mutation in the PEX11β gene. J Med Genet (2012) 1.17
Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma. Eur J Cancer (2007) 1.15
High delta-like 1 expression in a subset of neuroblastoma cell lines corresponds to a differentiated chromaffin cell type. Int J Cancer (2003) 1.11
A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Mol Cancer (2010) 1.10
Prevalence of rib anomalies in normal Caucasian children and childhood cancer patients. Eur J Med Genet (2005) 1.09
Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma. Cell Mol Life Sci (2009) 1.09
Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res (2003) 1.09
Pulmonary function impairment measured by pulmonary function tests in long-term survivors of childhood cancer. Thorax (2011) 1.08
beta-Ureidopropionase deficiency: an inborn error of pyrimidine degradation associated with neurological abnormalities. Hum Mol Genet (2004) 1.08
Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res (2003) 1.08
Inactivation of the peroxisomal ABCD2 transporter in the mouse leads to late-onset ataxia involving mitochondria, Golgi and endoplasmic reticulum damage. Hum Mol Genet (2005) 1.06
The peroxisomal ABC transporter family. Pflugers Arch (2006) 1.05
Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review. Cancer Treat Rev (2009) 1.05
PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol (2008) 1.05
Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Hum Mol Genet (2010) 1.03
Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J (2002) 1.02
Anthracycline cardiotoxicity in children. N Engl J Med (2004) 1.01
Lovastatin in X-linked adrenoleukodystrophy. N Engl J Med (2010) 1.01
Longitudinal assessment of health-related quality of life in preschool children with non-CNS cancer after the end of successful treatment. Pediatr Blood Cancer (2008) 0.97
Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem (2003) 0.97
X-linked adrenoleukodystrophy: pathogenesis and treatment. Curr Neurol Neurosci Rep (2014) 0.96
Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes Chromosomes Cancer (2011) 0.96
Characterization of the human omega-oxidation pathway for omega-hydroxy-very-long-chain fatty acids. FASEB J (2008) 0.96
Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocr Relat Cancer (2011) 0.95
Substrate preference of stress-activated phospholipase D in Chlamydomonas and its contribution to PA formation. Plant J (2003) 0.95
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev (2013) 0.95
Gene expression profiling in response to the histone deacetylase inhibitor BL1521 in neuroblastoma. Exp Cell Res (2005) 0.94
X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from a family with a novel PRPS1 mutation. Orphanet J Rare Dis (2014) 0.93
Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev (2010) 0.93
Complete beta-oxidation of valproate: cleavage of 3-oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase. Biochem J (2002) 0.92
Histone deacetylase inhibitor BL1521 induces a G1-phase arrest in neuroblastoma cells through altered expression of cell cycle proteins. FEBS Lett (2005) 0.92
A very long-chain acyl-CoA synthetase-deficient mouse and its relevance to X-linked adrenoleukodystrophy. Hum Mol Genet (2003) 0.90
Nutritional status at admission of children with cancer in Malawi. Pediatr Blood Cancer (2008) 0.90
Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur J Cancer (2011) 0.90
Ganciclovir nucleotides accumulate in mitochondria of rat liver cells expressing the herpes simplex virus thymidine kinase gene. J Gene Med (2003) 0.90
Hydrogen sulfide donor NaHS reduces organ injury in a rat model of pneumococcal pneumosepsis, associated with improved bio-energetic status. PLoS One (2013) 0.90
Omega-oxidation of very long-chain fatty acids in human liver microsomes. Implications for X-linked adrenoleukodystrophy. J Biol Chem (2006) 0.89
Contiguous gene deletion of ELOVL7, ERCC8 and NDUFAF2 in a patient with a fatal multisystem disorder. Hum Mol Genet (2009) 0.89
Fatty acid omega-oxidation as a rescue pathway for fatty acid oxidation disorders in humans. FEBS J (2010) 0.89
Mannose-binding lectin (MBL) substitution: recovery of opsonic function in vivo lags behind MBL serum levels. J Immunol (2009) 0.89
Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol Pharmacol (2013) 0.89
Prevalence of congenital heart defects in neuroblastoma patients: a cohort study and systematic review of literature. Eur J Pediatr (2008) 0.89
Clinical, biochemical and molecular analysis of 13 Japanese patients with β-ureidopropionase deficiency demonstrates high prevalence of the c.977G > A (p.R326Q) mutation [corrected]. J Inherit Metab Dis (2014) 0.89
6-mercaptopurine inhibits atherosclerosis in apolipoprotein e*3-leiden transgenic mice through atheroprotective actions on monocytes and macrophages. Arterioscler Thromb Vasc Biol (2010) 0.89
Evaluation of late adverse events in long-term wilms' tumor survivors. Int J Radiat Oncol Biol Phys (2010) 0.88
The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2. Oncogene (2002) 0.88
Analysis of carnitine biosynthesis metabolites in urine by HPLC-electrospray tandem mass spectrometry. Clin Chem (2002) 0.88
Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst Rev (2011) 0.87
Surveillance of hepatic late adverse effects in a large cohort of long-term survivors of childhood cancer: prevalence and risk factors. Eur J Cancer (2012) 0.87
Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines. Eur J Cancer (2006) 0.87
Should anthracyclines and dexrazoxane be used for children with cancer? Lancet Oncol (2011) 0.87
Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur J Cancer (2006) 0.87
Malnutrition and neutropenia in children treated for Burkitt lymphoma in Malawi. Pediatr Blood Cancer (2009) 0.87
The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells. Biochem Pharmacol (2004) 0.86
Increased plasma carnitine concentrations in preeclampsia. Obstet Gynecol (2004) 0.86
Bezafibrate lowers very long-chain fatty acids in X-linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation. J Inherit Metab Dis (2012) 0.86
Psychosocial indicators of health-related quality of life in children with cancer 2 months after end of successful treatment. J Pediatr Hematol Oncol (2007) 0.86
Coping and family functioning predict longitudinal psychological adaptation of siblings of childhood cancer patients. J Pediatr Psychol (2004) 0.86
Identification of BIRC6 as a novel intervention target for neuroblastoma therapy. BMC Cancer (2012) 0.86
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev (2010) 0.86
Cholestasis is associated with hepatic microvascular dysfunction and aberrant energy metabolism before and during ischemia-reperfusion. Antioxid Redox Signal (2012) 0.86
Acute malnutrition is common in Malawian patients with a Wilms tumour: A role for peanut butter. Pediatr Blood Cancer (2009) 0.86